Danish insulin giant Novo Nordisk (NOV: CO ) has sold full development and commercialization rights to the anti-NKG2A antibody, a first-in-class immune checkpoint inhibitor ready for Phase II development in oncology to French drugmaker Innate Pharma (IPH: FP).
Novo Nordisk conducted a large Phase I safety trial with anti-NKG2A in patients with rheumatoid arthritis, demonstrating a good safety profile for both iv and sc routes at single and multiple administrations. Novo Nordisk has decided to advance other compounds for further development in inflammation, including anti-NKG2D, currently in Phase II development and generated within the collaboration between Innate Pharma and Novo Nordisk.
Will receive 600,000 shares as part of the accord
Under the terms of the deal, Novo Nordisk will receive 2 million euros ($2.7 million) in cash and 600,000 shares of the Marseille-based company for licensing anti-NKG2A to Innate and be eligible to a total of 20 million euros in potential registration milestones and single-digit tiered royalties on future sales. The acquisition of the Innate shares is subject to approval by Innate’s shareholders’ at an extraordinary general meeting on 27 March 2014. Novo Nordisk is already a minority shareholder in Innate Pharma.
Herve Brailly, chief executive of Innate Pharma noted: "This is a superb opportunity for Innate Pharma. In addition to lirilumab partnered to Bristol-Myers Squibb and currently in Phase II, we now have a proprietary Phase II ready, first-in-class, immuno-modulating antibody with favorable Phase I safety data and the promise of broad development potential. Our initial clinical development plan is in oncology, and we expect to start the clinical program before the end of this year. This license consolidates Innate Pharma’s leadership in immuno-modulating antibodies targeting the innate immune system."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze